Diabetes Connections | Type 1 Diabetes

Jisel Parra had a rocky start with diabetes – as a teen her type 1 was initially misdiagnosed and she struggled with support and mental health. But she found ways to find community and gradually started to thrive with T1D. These days, Jisel runs A Tad Too Sweet, which makes trendy medical bracelets. She has a career outside of diabetes and has two children. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: Abbott recalls Freestyle Libre readers (not the sensors, see below for more information), Medicare expands CGM coverage for more people with type 2, a new study looks at the transition for children with T1D to adults and why patients aren't being served well during that time, and much more! Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by Athletic Greens AG1 by Athletic Greens is daily nutrition made really simple. XX If you've got an Abbott Libre reader – check it for a huge recall. The company is issuing a class one – that's the most serious -recall of all readers distributed in the U.S. from November 2017 to February 2023, totaling more than 4 million devices. The recall is due to the potential overheating, sparking, or fire that may occur when the readers are charged with non-Abbott adapters or USB cables, or when they are damaged or exposed to liquids. Abbott-provided USB cables and power adapters limit the current to safely charge the battery, whereas third-party cables and adapters may allow much higher power, increasing the risk of fire. Abbott has reported 206 incidents related to this issue, including at least seven fires and one injury, but no deaths. I've got the phone number to call and more information in the show notes at d-c dot com. This recall only applies to those using the external reader device, not those using their smartphone. Contact Information Users with questions about this recall should contact Abbott Customer Service at 1-855-632-8658, available 7 days a week from 8AM to 8PM Eastern Time, excluding major holidays. https://www.fda.gov/medical-devices/medical-device-recalls/abbott-recalls-readers-used-freestyle-libre-freestyle-libre-14-day-and-freestyle-libre-2-flash XX A big policy change coming next week - The Centers for Medicare and Medicaid Services will expand continuous glucose monitor coverage to more people with type 2 diabetes. That starts April 16th, this Sunday if you're listening as the episode first drops. The expanded coverage applies to people using a basal only routine, as well as others who have a history of what has been classified as "problematic hypoglycemia." Bottom line for those with type 2 – check with your doctor to see if a CGM is now covered October.https://diatribe.org/medicare-expands-cgm-continuous-glucose-monitor-coverage-type-2-diabetes XX Montana lawmakers are considering a bill that would require insurance companies to cover CGMs for people with Type 1 and Type 2 diabetes. House Bill 758 has broad support from lawmakers, but it faces opposition from insurance companies and some providers. That opposition focuses on the cost, whether a CGM is medically necessary at all stages of diabetes, and the possibility that CGM manufacturers will raise their prices if there is an insurance mandate. Blue Cross and Blue Shield of Montana, the state's largest insurer, estimates the bill, if passed, would cost the organization nearly $5 million a year. The BCBS spokesperson also says ""These things are a convenience," https://khn.org/news/article/montana-potential-bill-insurance-covering-continuous-glucose-monitor/ XX Short-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with an increased risk for heart failure hospitalization among patients with type 2 diabetes (T2D), according to a Danish registry study. Among over 300,000 patients with T2D, short-term use of NSAIDs was associated with a relative 43% increased risk of a first-time heart failure hospitalization in the subsequent 28 days. NSAIDs increased the risk of heart failure even more in type 2 diabetics who were 80 or older (78%) or who had high blood sugar levels (68%), the results showed. Those who'd never used an NSAID before had the worst reaction, with their heart failure risk nearly tripling. However, heart failure was not associated with using NSAIDs in people with well-controlled diabetes and normal blood sugar levels. https://www.medpagetoday.com/cardiology/chf/103936 XX New study from Boston Children's Hospital shows the transition from child to young adult managi

Dr. Bryce Nelson is one of the first doctors in the country to administer the new Tzield to delay the onset of type 1. He's been involved with TrialNet, identifying those who have the genetic markets for T1D and says that research was exciting but frustrating because they had no treatment. Now, they're looking at a possibly new way of talking about T1D. Dr. Nelson is the Chief of Endocrinology at Children's Hospital of Richmond at VCU Dr. Nelson takes us through the process of using Tzield – which was researched under the name teplizumab – from identifying the patient, to treatment to what happens next. His first patient, William Troutman, is a North Carolina teenager. William's mom joined me a few weeks ago to tell their side of the story. Listen to our episode with Amanda Troutman: https://diabetes-connections.com/delaying-a-t1d-diagnosis-with-tzield-a-deep-sigh-of-relief-for-a-little-while/ This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

This week… one of the oldest diabetes companies is looking ahead – Once part of BD, makers of needles and syringes, Embecta is now working on new technology like a patch pump. I'm talking to CEO Dev Kurdikar about moving the company forward, while still serving the patient community that relies on their established technology. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

Dr. Maureen Michele is a pediatrician whose daughter had already survived a cancer diagnosis, when she was later diagnosed with 1 diabetes. In fact, Dr. Michele knew enough to test for T1D, so mom and daughter found out together, in the school bathroom. The family is now on the other side of what she calls this overwhelming chaos.. and what they've learned can help others.. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Maureen's Book: Reclaiming Life Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: Insulin-maker Sanofi lowers its prices and also acquires Provention, clinical trials begin on an out-patient surgery that could help treat type 2 diabetes, a swimmer DQ'd for the tape on his CGM gets the systemic changes he'd pushed for and more! Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Episode Transcription: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by Athletic Greens ● AG1 is way more than greens. XX XX Provention Bio's been in a news a lot lately after the approval of Tzield to delay the development of type 1. Now French insulin-maker Sanofi has agreed to acquire it. The deal builds on an existing co-promotion agreement and gives Sanofi full ownership of the drug. Sanofi makes long acting Toujeo and Lantus. Interestingly, Sanofi has said they're gong to stop further work on type 2 diabetes and obesity drugs. They also joined Novo Nordisk and Eli Lilly in dropping the price of insulin in the US. https://www.reuters.com/markets/deals/frances-sanofi-acquire-us-based-provention-bio-29-bln-2023-03-13/ XX Insulin pricing staying in the news as Senators Bernie Sanders and Cori Bush introduced legislation to cap the price at 20-dollars. They point out the recent prices cuts don't apply to everyone and are still at the whim of the manufacturers. XX California signs up with Civica Rx to produce its own insulin and sell it at an affordable price. The $50 million investment will allow California to produce insulin to be sold at prices capped at $30 per vial and $55 for a box of five prefilled pens, Civica Rx said (PDF) in a release. The agreement is part of the state's CalRx Biosimilar Insulin Initiative. Utah-based Civica Rx is a nonprofit, social welfare manufacturer of generic drugs. This is a long way off.. Civica Rx still needs to gain approval for its biosimilar versions of Sanofi's Lantus (gargline), Eli Lilly's Humalog (lispro) and Novo Nordisk's Novolog (aspart). The cost of insulin would be same for all patients regardless of their insurance situation https://www.fiercepharma.com/manufacturing/california-invests-50m-partner-civica-rx-insulin-manufacturing XX XX (skip?) Millions of Americans with diabetes have cheered as drugmakers slashed the price of insulin, the lifesaving medication that treats the chronic disease. But those lower prices, which came amid government pressure to cap insulin costs and more competition from generics and biosimilars, are only one part of the cost of treating the disease, which causes elevated blood sugar that can damage the heart, eyes and kidneys if untreated. Over-the-counter medical supplies to monitor glucose levels and administer medications can make up the largest portion of a patient's costs. A 2020 JAMA Internal Medicine report found that children and adults with private health insurance spent more out-of-pocket on diabetes-related supplies than on insulin A person with diabetes who uses insulin typically spends $4,882 a year on treatment if they have insurance. Of that, $3,992 is spent on supplies, according to an analysis by GoodRx, or more than 80% of the annual expense of managing the disease https://www.usatoday.com/story/money/personalfinance/2023/03/19/cost-diabetes-supplies-worse-than-insulin/11472381002/ XX New trial of a technique to slow the progression of type 2 diabetes. It's a simple outpatient surgery conducted in the early stages of diagnosis. The procedure targets the doo-oh-DEE-num duodenum, the first section of the small intestine just past the stomach. This organ plays a key role in digestion, including regulating insulin and blood glucose levels. In patients with type 2 diabetes, the cells that line the duodenum have become damaged, and the trial's hypothesis is that removing these cells helps healthy ones to grow back, improving the regulation of blood glucose levels. Patients in the clinical trial would undergo an endoscopy to insert a device into the doo-oh-DEE-num duodenum, which removes those dysfunctional cells with a series of electrical pulses. The procedure itself is only minimally invasive – it takes about an hour, it's conducted under a general anaesthetic and the

When the FDA cleared the 3 FreeStyle Libre 2 and FreeStyle Libre 3 (iCGM) system sensors for integration it meant a big leap forward to interoperability. For the first time in the US, insulin pumps can work with two different sensors.. Libre and Dexcom. This week, Stacey talks to Dr. Jordan Pinsker, medical director for Tandem Diabetes Care, about the upcoming Libre integration, the Mobi pump that's in front of the FDA right now, and much more. Dr. Pinsker has extensive experience with automated systems – he's been there since close to the beginning and we talk about the long process to bring them to market, how they're changing lives and what is still yet to come. More about the Libre approval: https://beyondtype1.org/freestyle-libre-aid-clearance/ More about Dr. Pinsker: https://www.tandemdiabetes.com/providers/bio/jordan-pinsker This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

Ginger Vieira is here to talk about her new book – she's written on everything from pregnancy with diabetes to exercise to her new series of children's books. But she's such a well-versed advocate, I had to ask her about her work at the T1D Exchange and all about her use of Afrezza. Why does she love it so much and what does she want you to know about using inhaled insulin? This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More about Ginger: https://www.gingervieira.com/ Diabetes Doodles: https://diabetesdoodles.com/ Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: learning more about Lilly's plan to lower the price of some insulins, Abbott's Libre 2 and Libre 3 get FDA approval to work with automated insulin delivery systems like Control IQ and Omnipod 5, Medicare expands coverage of CGMs for people with type 2, an old blood pressure medication shows promising results in a T1D study, and more! Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Episode transcription: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by Athletic Greens XX Insulin prices https://www.statnews.com/2023/03/06/eli-lilly-insulin-medicaid-rebates/ Drugmaker Eli Lilly & Co. on Wednesday said it will cut prices of its most commonly prescribed insulins by 70% and cap monthly out-of-pocket costs at $35 at certain retail pharmacies for people who have private insurance. Lilly will list its Lispro injection at $25 a vial effective May 1 and slash the price of its Humalog and Humlin injections by 70% starting in the fourth quarter. The announcement comes amid growing federal pressure to lower the cost of insulin. The Inflation Reduction Act capped insulin prices for Medicare beneficiaries at $35 per month but did not protect people with private insurance or who don't have coverage from higher prices. Eli Lilly would've had to pay Medicaid about $150 for each vial of insulin used in the program if it hadn't dramatically cut the list prices for some of its older products this week. The company was about to run into a Medicaid penalty for raising the price of it's drugs faster than the rate of inflation. https://www.cnbc.com/2023/03/01/lilly-cuts-insulin-prices-70percent-cap-prices-at-35-per-month-for-private-insurance.html XX The FDA has cleared Abbott's Freestyle Libre 2 and Libre 3 continuous glucose monitors (CGM) for integration with automated insulin delivery (AID) systems. These devices have also been cleared for younger children, extended wear time, and for use during pregnancy. The FDA on March 6 cleared Abbott's Freestyle Libre 2 and Freestyle Libre 3 CGM for use with automated insulin delivery (AID) systems. AID systems connect a CGM, insulin pump, and smartphone to automatically adjust insulin dosing in real-time in response to changing glucose levels. These systems have been demonstrated to help many people with diabetes improve their time in range and reduce the time spent thinking about managing glucose each day. With this new clearance from the FDA, Libre 2 and 3 CGMs and the connected smartphone app will soon integrate with insulin pumps to adjust insulin dosing. Freestyle Libre 2 and Libre 3 CGMs were previously cleared for use by people with diabetes ages 4 and older. Freestyle Libre 3, cleared in the United States in May 2022, is compatible with both iOS and Android smartphones. Among several upgrades made from Libre 2, Libre 3 no longer requires users to manually scan their device with their smartphone to see glucose levels – data is sent to the mobile app automatically. In the announcement, Abbott said the device has also been cleared for an extended wear time of 15 days, for use by children as young as age 2, and for use during pregnancy by women with type 1, type 2, or gestational diabetes. Current users of Libre CGMs should note that the devices available now cover people with diabetes ages 4 and older, can be worn for 14 days, and are not cleared for use during pregnancy. According to Abbott, the modified Libre 2 and 3 sensors will be available in the U.S. later this year. https://diatribe.org/fda-clears-freestyle-libre-2-and-3-use-automated-insulin-delivery XX Medicare will cover continuous glucose monitors for a broader group of patients, starting in April, according to an updated policy published by the Centers for Medicare and Medicaid Services. The policy change included broader language and also came earlier than expected, making it a "welcome surprise," and could double the market for the devices, J.P. Morgan analyst Robbie Marcus wrote in a research note. Dexcom and Abbott Laboratories had expected coverage to start in mid-year. In an earlier draft of coverage guidelines, CMS had suggested covering the devices for p

Last fall, Tzield was approved to delay type 1 diabetes in people predicted to develop it. This week, I'm talking one of the first families to use what used to be called Teplizumab for their son, as a regular patient, outside the clinical trials. How exactly does this all work? Who's eligible and how do you cover the enormous financial cost? Amanda Troutman talks about why they went through this process with her son, William. Their whole family was tested for the genetic markers after their daughter, Jenna, was diagnosed in 2020. As always, this podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Our previous episodes on Tzield: https://diabetes-connections.com/?s=teplizumab More about the Troutman family: https://www.vcuhealth.org/news/north-carolina-teen-among-first-in-us-to-receive-new-diabetes-drug Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

Dexcom's G7 has been available in the US for less than two weeks, but the company continues to look ahead. Part of the future? Their Type Zero group – which created Tandem's Control IQ – is working on a truly closed loop system. Chief Operating Officer Jake Leach spoke to Stacey from the recent ATTD Conference. Of course we also asked a bunch of your G7 questions and had a more in-depth discussion about CGM monitoring for people without diabetes. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

Infusion sets have always seems like the weak link of pumping for us. What good is the best algorithm and state of the art pump and CGM if the way it all attaches to the body is no good? New information shows infusion failures happen more than you may think. John Wilcox's company, DiaTech Diabetes, has an infusion set failure detection system. He's going to explains what that is, how it works and what you can do with the sets you have right now to make them more effective More here: https://diatechdiabetes.com/ This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: Dexcom G7 is now available in the United States, Insulet buys assets from Bigfoot and another California company, new studies about cannabis and type 1 and COVID and diabetes, different predictors of type 2 in women and men, plus scholarships for T1D students. Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Episode Transcription: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by T1D Exchange dedicated to improving outcomes for the entire T1D population XX Our top story. Today's the day. February 17th is the day Dexcom's G7 becomes available in the United States. Now.. whether you can get it still depends on your insurance, your doctor – a new prescription is needed – and the availability at your pharmacy. Whether you want to get it may depend on if you use a compatible pump system – the G7 will NOT work with Tandem's CIQ or Omnipod 5 for several more months. The G7 will be accessible to all Medicare patients with diabetes who meet the eligibility criteria as of today.. so no wait there. Much more to come on the launch I'm sure.. https://investors.dexcom.com/news/news-details/2023/Dexcom-G7-Continuous-Glucose-Monitoring-System-Will-Be-Available-to-Medicare-Beneficiaries-at-Launch/default.aspx?fbclid=IwAR0cKhAv5C8TMZ8v8f98rlhnvBQ0JkFj3SLRyc7RdMeOAO3_Tpl95cKNX20 XX People who've had Covid-19 have a higher risk of developing diabetes, and that link seems to have persisted into the Omicron era, a new study finds. Mounting evidence suggests Covid-19 infections are tied to a new diagnosis of diabetes, though it's not clear whether this relationship is a coincidence or cause-and-effect. Big study here, 23,000 adults who'd had Covid-19 at least once. The raw data showed that people who'd had Covid-19 had higher risks of being diagnosed with diabetes, high cholesterol and high blood pressure after their infections. But when the researchers adjusted those numbers to account for the benchmark diagnosis, only the risk of diabetes remained significantly elevated. Covid-19 increased the odds of a new diabetes diagnosis by an average of about 58%. The new study is notable because it adds recent data, said Wander, who was not involved in the research. It also used strategies to try to address shifts in health care during the pandemic. Another strength of the study was that it included people who were diagnosed between March 2020 and June 2022, so it was able to estimate the risk even after the Omicron variant swept through the US. https://www.cnn.com/2023/02/14/health/covid-diabetes-risk-study/index.html XX Insulet making a couple of interesting acquisitions.. $25 million in assets from Automated Glucose Control LLC in California. And the same amount $25 million of assets from Bigfoot Biomedical. AGC and Insulet have had a partnership since 2016 which mostly involved the algorithm that led to Omnipod 5. Bigfoot has also claimed patents regarding more hands-off insulin delivery, The acquisition effectively doubles Insulet's IP portfolio, Eric Benjamin, the company's executive VP of innovation, strategy and digital products, said in a press release. XX Dr. Halis Akturk and colleagues began noticing patterns among people with T1D in Colorado hospital emergency departments (ED) after cannabis was legalized in the state. They have since conducted several nationwide retrospective studies on those living with T1D that also use cannabis, including hospitalization records and T1D Exchange Registry participant surveys. They found that T1D participants had repeated return visits to the ED in the following weeks, and DKA was frequently misdiagnosed. Based on that research, Dr. Akturk's team has recently developed a key to differentiating between DKA and a new syndrome that mimics DKA, one they've named HK-CHS: Hyperglycemic Ketosis-Cannabis Hyperemesis Syndrome. To treat HK-CHS, your care team will typically increase fluids, treat the high blood glucose with insulin, and balance your electrolytes, or anion gap. You will be advised to stop using cannabis until the symptoms resolve. These treatments will bring your blood glucose levels back into target range and get your gut mov

When you're a parent with diabetes, your kids often learn about diabetes before they can read or write. They know you might beep or take shots or wear a CGM and they often become diabetes helpers in serious circumstances. This week, Dr. Phyllisa Deroze talks about why she wrote a new book "Diabetes Helpers." Dr. Deroze began blogging at DiagnosedNOTdefeated.com almost immediately after being diagnosed with diabetes in 2011. The following year she founded Black Diabetic Info; a website dedicated to helping close gaps of cultural incompetence around diabetes information. Amazon link to Diabetes Helpers This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Our previous episode with Dr. Deroze about how diabetes is misrepresented in media: Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

Tandem Diabetes has made some big moves recently, acquiring two new companies – one makes infusion sets, the other a patch pump called Sigi, and their tiny Mobi pump is in front of the FDA right now. We're finding out how it may all come together from Tandem's EVP and Chief Strategy Office Elizabeth Gasser. We talk about how these acquisitions have changed Tandem's road map – you may remember they released that look into the future last year – G7 integration, software updates and a lot more. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. 2022 Episode with Tandem, includes links to the original 5-year road map Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

It's In the News, a look at the top stories and headlines from the diabetes community happening now. This week, Dexcom sets a US release date for the G7, we find out whether Tandem will be a Tidepool Loop partner now that Insulet and Medtronic are out, Omnipod Eros to be discontinued, a new study says there's a better age to test kids for type 1, a new smart insulin pen sensor can also be used to track dosing of GLP-1 medications, a new twist in the Faustman study of the TB vaccine to treat diabetes, the Sims 4 update brings CGMs to the game and more. Links and transcript below Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Episode Transcription: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by VIVI Cap – confidence on the go that keeps your insulin protected in hot or cold XX Learning a bit more about the Tidepool pump partnership, at least who it won't be. When Tidepool Loop approval was announced last month, it came without the original pump partners, Omnipod and Medtronic. CEO Howard Look said they do have a pump partner but that they're not ready to announced yet. I spoke to Tandem for next week's episode and they say its' not them. Quote "That's not part of our roadmap, it's not an integration we're working on." XX Insulet announces it will discontinue the original Omnipod system. In a letter to healthcare professionals, the company says the system, referred to as Eros or Omnipod Classic will be discontinued at the end of this year. It's no longer available to new patients and existing customers will be transitioned to Dash or Omnipod 5. I'll link up the letter in the show notes. "Dear healthcare professionals, We have made the decision to discontinue the original omnipod insulin management system in the us after December 31 2023. This system is often referred to omnipod eros or omnipod classic. Insulet will continue to support the omnipod system throughout this year to allow existing patients ample time to transition to newer omnipod technology such as Omnipod dash or Omnipod 5. please note this product is no longer available for new patients in the US. After December 31, 2023 Insulet will not be able to guarantee the availability of the omnipod system supplies. " https://www.facebook.com/photo/?fbid=10225188520677483&set=a.1253748061199 XX Civica continues to move ahead with more affordable insulin, announcing that Ypsomed will make and supply their pens. Civica plans to produce three insulin biosimilars priced at no more than $30 per vial and no more than $55 for a box of five pen cartridges. Contingent on FDA approval, Civica anticipates that its insulins will be available for purchase beginning as soon as 2024. XX New study shows screening kids at risk for type 1 diabetes only once – at age ten – is very effective in detecting the condition by the age of 18. These researchers also say "Almost no one" who is islet autoantibody negative at age 10 years despite a high familial risk for type 1 diabetes will develop clinical diabetes by the age of 18. Full study published in the Lancet. https://www.medwirenews.com/diabetes/age-10-years-optimal-type-1-diabetes-screening-point/23957596 https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(22)00350-9/fulltext?fbclid=IwAR2kRNyGg6lnq3ZWsFkXnCvkeNiisg9mE2bbN_OnGiLrUpcHKXAaff3OkE4 XX The nonprofit public health advocacy group the Physicians Committee issued a formal complaint that a recent CBS "60 Minutes" segment was a promotion for Novo Nordisk's obesity drug, Wegovy, that was dressed up as a news segment. The Washington, D.C.-based group has filed a complaint with federal bodies alleging that the CBS "60 Minutes" segment that aired on New Year's Day breached the FDA's "fair balance" rules for drug ads. The Committee said in a release that the feature failed to talk about alternatives to the drug or about other weight-loss methods; that only experts "paid by Novo" were used in the program; and that the piece used overly promotional language. This has caused Wegovy supply issues for Novo which, coupled with manufacturing problems, only deepened bumps in production last year for the drug and led to an official shortage of the drug in 2022. A spokesperson for Novo Nordisk told Fierce Pharma Marketing: "Novo No

The US FDA has approved Tidepool Loop, an app designed to automate insulin dosing. Born out the do-it-yourself, "we are not waiting" movement, it has designs and features not in the first wave of commercial automated systems like Omnipod 5 and Tandem's Control IQ. CEO Howard Look talks to Stacey about what was approved here and what Tidepool Loop is all about. If you've followed this story closely, you're going to be surprised to learn about a few changes that have happened along the road to approval.. and to learn the questions that Tidepool will have to answer next. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Learn more about Tidepool: https://www.tidepool.org/ Our previous episodes with Howard Look: Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

How are those New Year's resolutions going? By this time, it's possible you've given up. But maybe it's just that you've set your goals a little too high. This week, Stacey talks to Ben Tzeel, Founder of Your Diabetes Insider, Registered Dietitian, Certified Diabetes Care & Education Specialist, Certified Strength & Conditioning Specialist. Ben also lives with type 1. We're going to talk about how to make the changes you want in a way that helps you stick with it. AND he's going to share some of his experience in a trial where he ate – no joke – about four thousand calories at one meal! This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's books! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Learn more about OMNIPOD* *Learn more about AFREZZA* *Learn more about DEXCOM*

It's In the News, a look at the top stories from the diabetes community from the last seven days. This week: Cost Plus pharmacy starts putting out feelers about insulin, asking people to take part in a pilot program, EO Flow looks at the US market for their new patch pump, quite a few new studies about type 2 diabetes drugs, a study about slowing down type 1 in kids and much more! Learn more about the T1D exchange and drive research that matters! www.t1dexchange.org/stacey Check out Stacey's books! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Learn more about OMNIPOD* *Learn more about AFREZZA* *Learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by The T1D Exchange - Help drive research that matters. XX Possible new player in the US Patch pump business. EO Flow has submitted a 510(k) application to the FDA for its EOPatch wearable, disposable insulin pump. EO Flow is based in California and has launched the pump in South Korea. The company also has FDA breakthrough device designation on an integrated artificial pancreas. The website says EOPancreas is a wearable disposable artificial pancreas system that integrates a continuous glucose sensor and an insulin pump in one small wearable module and autonomously controls insulin infusion. They're looking for a US partner for the pump and hope to launch in 2024. http://www.eoflow.com/eng/eopatch/eopatch_010100.html https://www.drugdeliverybusiness.com/eoflow-submits-insulin-patch-pump-fda-clearance/ XX Your time in range before getting a COVID vaccine may predict your body's response. This was a small study, 25 patients with type 1 who received two doses of a COVID vaccine. Researchers followed the group two weeks before before and six months after the shots. Main outcome measures: The primary exposure and outcome measures were pre-vaccination glucose control, and antibody response after vaccination, respectively. Patients meeting the recommended pre-vaccination glucose targets of TIR (≥70%) and TAR (≤25%), developed stronger neutralizing antibody titres (p https://pubmed.ncbi.nlm.nih.gov/36611249/ XX New study in kids with type 1 seems to show that the drug golimumab – brand name Simponi – can help preserve beta cell function. This is the Tiger study which included people ages 6 to 21 years old with T1D and given either the drug or a placebo for 52 weeks the off the drug for another year. The group taking the drug used less insulin and had a higher c peptide level in the time after the medication stopped, indicating that there was a difference. https://diabetesjournals.org/care/article-abstract/doi/10.2337/dc22-0908/148228/Two-Year-Follow-up-From-the-T1GER-Study-Continued?redirectedFrom=fulltext XX New study confirming what a lot of you already know, Metformin failure in people with type 2 diabetes is very common, particularly among those with high A1c levels at the time of diagnosis. An analysis of electronic health record data for more than 22,000 patients starting metformin at three US clinical sites found that over 40% experienced metformin failure. This was defined as either failure to achieve or maintain A1c less than 7% within 18 months or the use of additional glucose-lowering medications. "These results call into question the ubiquitous use of metformin as the first-line therapy and suggest a more individualized approach may be needed to optimize therapy," they add in their article published online in the Journal of Clinical Endocrinology and Metabolism. The investigators identified a total of 22,047 metformin initiators from three clinical primary care sites: the University of Mississippi's Jackson centers, which serves a mostly African American population, the Mountain Park Health Center in Arizona, a seven-clinic federally qualified community health center in Phoenix that serves a mostly Latino population, and the Rochester Epidemiology Project, which includes the Mayo Clinic and serves a primarily White population. https://www.medscape.com/viewarticle/986994 XX The FDA has approved a label update for semaglutide that allows the drug to be used in addition to diet and exercise as a first-line option to improve glycemic control in adults with type 2 diabetes. The brand name here is Wegovy. With its initial FDA approval in 2019, semaglutide became the first and only glucagon-like peptide-1 (GLP-1) analog in pill form. https://www.pharmacytimes.com/view/fda-approves-label-update-for-semaglutide-allowing-use-as-first-line-option-for-adults-with-type-2-diabetes XX Merk says it's diabetes drugs Januvia and Janumet have become contaminated with a potential carcinogen.. and it can resolve the problem by the end of the year. The company submitted a report

We've got new information about Dexcom's G7 launch and much more. CEO Kevin Sayer says it'll be available in the US before the end of March. Sayer joins us from the J.P. Morgan Healthcare Conference in San Francisco. He talks about Dexcom's pump partners, when the FDA will let them put in features they already have in Europe but not here, and answers a lot of your questions. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Stacey mentioned this link during the episode: www.dexcom.com/g6-medicare Check out Stacey's books! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Learn more about OMNIPOD* *Learn more about AFREZZA* *Learn more about DEXCOM*

Dad and daughter, Randall and Emma Barker, were diagnosed at the same age (ten) and have a few other coincidences around their experiences with T1D. They have a close relationship and this week, they share their story. The Barkers are here to talk about eye health – we get help from the American Diabetes Association's Dr. Laura Hieronymus to talk about treatment and prevention of complications, which Randall has. But we also talk about what it's been like for Emma to watch her father live with type 1 and then be diagnosed herself and Randall shares his own feelings of guilt.. and pride. This is a good one. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's books! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! Learn more about Omnipod Learn more about Afrezza Learn more about Dexcom Learn more about Vivi Cap

It's In the News, a look at the top stories from the diabetes community from the last seven days. This week: predictions of a huge increases in cases of type 2, insulin prices are capped for those with Medicare, Omnipod commits to a basal-only pump for people with type 2, and more! In the news is brought to you by Athletic Greens! Find out more: https://athleticgreens.com/stacey Check out Stacey's books! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! Learn more about Afrezza Learn more about Dexcom Learn more about Omnipod Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by Athletic Greens! AG1 is way more than greens it's daily nutrition made really simple XX New study says the number of young people in the United States with diabetes will increase by nearly 700% over the next 40 years. This was a projection study using numbers from the past 20 years and was published in the journal Diabetes Care. The CDC believes that "the increasing prevalence of childhood obesity," as well as "the presence of diabetes in people of childbearing age," could be two reasons for why the number of young Type 2 diabetics has increased so rapidly. There is some evidence that COVID 19 may also have something to do with more cases of diabetes but there isn't enough data to know for sure. https://www.wibw.com/2023/01/03/cdc-predicts-huge-spike-diabetes-among-young-adults-next-40-years/ XX As of January first, the monthly out-of-pocket cost of insulin is capped at $35 for seniors on Medicare. That's part of the Inflation Reduction Act in effect on Jan. 1. In August, Republicans blocked a provision in the bill that would have capped the out-of-pocket cost of the drug for everyone on private insurance. There was no provision for the uninsured. It's not clear whether insulin pricing will come up again during this new congress. https://www.nbcnews.com/health/health-news/insulin-cost-cap-people-diabetes-no-benefit-rcna58165 XX Insulet is planning a basal only pump, looking at the type 2 market to compliment their Omnipod pump. The newly announced device is designed for patients with Type 2 diabetes who receive daily or weekly injections of basal insulin. Unlike Insulet's other devices, it doesn't have a controller, but has a built-in basal conversion rate. They hope to have it on the market by 2024. In an earnings call late last year Insulet announced a 42-percent increase in revenue in the US. They'll plan a European launch of Omnipod 5 in mid-2023. https://www.medtechdive.com/news/insulet-omnipod-5-q3-earnings-record-PODD/635811/ XX Beta Bionics appoints a new Chief Medical Officer as the company quote - for the commercial launch of the iLet Bionic Pancreas System. As of right now, the iLet is still in front of the FDA but it sounds like it may be getting close to approval. Dr. Steven Russell is the new CMO here.. Dr. Russell has directed nearly all of the bionic pancreas clinical trials. The bionic pancreas – renamed the iLet a few years ago – operates using only the person's body weight, no basal rates or other settings – and input about the size of meals, not carb counts. https://www.newswire.com/news/beta-bionics-appoints-dr-steven-russell-as-chief-medical-officer-in-21920409 XX Lilly's Emergency Glucagon Kit is now out of production. They announced last year that they will discontinue the red box emergency kit at the end of 2022 in the US. The company says with newer options like Baqsimi nasal spray, Gvoke and Zegalogue pens, the demand isn't there. If you do prefer the older kit – really the only way to do those mini-glucagon shots some people really like – there are still two options – Novo's GlucaGen Hypo Kit – the orange box and a generic made by Amphastar. https://diatribe.org/glucagon-options-expand-lilly-discontinues-emergency-kit XX Another move forward to islet transplantation. Houston Methodist Medical Center in Texas delivered islet cells and immunotherapy directly into a 3D-printed device named NICHE, which is similar to a bioengineered pancreas. It's about the size of quarter and goes under the skin. There's a tiny port that means the device can be refilled with medication. These researchers say they're probably three years from human trials. https://www.jpost.com/health-and-wellness/article-726001 XX The US Food and Drug Administration has approved semaglutide brand name Wegovy for teenagers with obesity. When Wegovy was approved for use in adults with obesity in June 2021, it was labeled a "game changer." The results in teens – who also received what they call lifestyle intervention – were close to the results seen after bariatric surgery. Wegovy is a once weekly shot – it's also sold with a lower dose as a type 2 treatment with the bran

Happy new year! What will 2023 bring for diabetes technology? We bring our best guesses to the table and we take a look back at what we said would happen last year. Stacey is joined by Chris Wilson on a Twitter Spaces Chat and you'll also hear from Mike Hoskins for a look back to 2022. Mike is currently an editor at Healthline and formerly the managing editor at DiabetesMine. Chris Wilson, is a longtime advocate and information junkie who just marked 25 years with type 1. Chris will tell you that for much of his time with diabetes he didn't have insurance and didn't use a lot of the more advanced tech.. and now he really follows it all very closely, takes part in clinical trials and is designing his own pretty incredibly sounding DIY closed loop features. None of the three have financial stakes in these companies, past some stocks that may be buried in mutual funds – we don't' own individual stakes in these companies. And their information is based on whatever is publicly available. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's our annual game show: Wait Wait Don't Poke Me! Taped earlier this year for the Mental Health Plus Diabetes Conference, this is a light hearted episode with games and trivia, all centered around diabetes. Our guests are Rob Howe, Taylor Daniel and Mark Heyman.. three terrific diabetes advocates who will introduce themselves and share more about their diabetes connections. There is a video version over on YouTube. Hope you play along with our silly games at home.. and enjoy! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

A student athlete diagnosed with type 1 just after her very first college season, Bri Caraquillo had reached her dream of playing lacrosse at Yale but had to figure it all out all over again after her diagnosis in May of 2020 Bri is part of the very first class of Dexcom U – a program that's happening under the new NIL ruling . We'll explain what that is, what it means for these student athletes and get advice from Bri about balancing it all. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's In the News, a look at the top stories from the diabetes community from the last seven days. This week: Tandem buys the maker of Sigi Pump, a reusable, rechargable patch pump, Lilly uncouples from Ypsomed, big study finds widespread adoption of insulin pumps among people with type 1, but not among people of color, a big look at vegetables studies and why potatoes are basically messing things up.. and a lot more! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Big new study about insulin pumps shows white patients are twice as likely to get one as Black patients, and better-educated, wealthier people are also more likely to be using one. Over 20 years, starting in 2001, these researchers saw a large increase in insulin pump use across all patients, but no change in distribution by race or socioeconomic status The study was recently published in the journal Diabetes Technology & Therapeutics. Recent data found that Black people had higher rates of severe diabetes-related complications compared with white folks. There is also a concern that these gaps will widen with the new automated insulin-delivery systems, worsening health inequality for subsets of youth with type 1 diabetes. https://www.usnews.com/news/health-news/articles/2022-12-13/insulin-pumps-ease-diabetes-care-so-why-are-black-patients-less-likely-to-get-one XX Tandem Diabetes snaps up a patch pump.. buying the Swiss company that makes Sigi. The Sigi Patch Pump is not yet available, it has FDA breakthrough designation. This is a rechargeable pump, you get two you can switch out, and the infusion set is disposable. It's set up to work with an AID system. We did an episode with SIGI earlier this year.. no word on what this might mean for Tandem's Mobi pump.. which is a tubed pump that's very small and was meant to compete with Omnipod.. before this news. https://www.businesswire.com/news/home/20221213005314/en/Tandem-Diabetes-Care-to-Acquire-Insulin-Patch-Pump-Developer-AMF-Medical XX Eli Lilly has pulled out of a partnership with Ypsomed that would have given it a branded insulin pump to sell in the U.S. Lilly struck a deal two years ago to commercialize YpsoPump under its own brand in the U.S. The partners have since worked to customize the pump, which has been sold in Europe since 2016, for the U.S. market. Ypsomed plans to push ahead with the U.S. expansion without Lilly, outlining plans to file with the Food and Drug Administration in the second half of next year and commercialize the pump with a new partner. This is the second pump partner Lilly has dropped. They had a prototype with a company called DEKA but quietly disbanded that partnership a few years ago. https://www.medtechdive.com/news/lilly-LLY-ypsomed-insulin-pump-split/638492/ XX New more aggressive targets for blood pressure and lipids are among the changes to the annual American Diabetes Association (ADA) Standards of Care in Diabetes. The document, long considered the gold standard for care of the more than 100 million Americans living with diabetes and prediabetes, was published December 12 "In this year's version of the ADA Standards of Care — the longstanding guidelines for diabetes management globally — you'll see information that really speaks to how we can more aggressively treat diabetes and reduce complications in a variety of different ways," ADA Chief Scientific and Medical Officer Robert A. Gabbay, MD, PhD, told Medscape Medical News. Other changes for 2023 include a new emphasis on weight loss as a goal of therapy for type 2 diabetes; guidance for screening and assessing peripheral arterial disease in an effort to prevent amputations; use of finerenone in people with diabetes and chronic kidney disease; use of approved point-of-care A1c tests; and guidance on screening for food insecurity, along with an elevated role for community health workers. https://www.medscape.com/viewarticle/985482 XX I love this story.. A new report says eating a diet rich in vegetables may not reduce the risk of type 2 diabetes. Why? Because usually, potatoes are included a as veggie in these studies, including fried potatoes, potato chips, and mashed potatoes increase the risk. In the study, participants who consumed the most vegetables — minus potatoes — had a 21% reduced risk of diabetes than those without substantial amounts of vege

This week.. after a year of deliberations, the US FDA approves the newest product from Dexcom, the G7. This is a much smaller device, with all-in-one sensor and transmitter, shorter warm up time and many more new features. Stacey talks with Dexcom's Chief Operating Officer Jake Leach. They do a lighting round of questions to learn more about what was – and was NOT – approved here. It's not exactly what's already on the market in Europe.. and we look ahead to what's next. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Previous episodes on the G7: https://diabetes-connections.com/?s=g7 Watch the interview on our YouTube channel: https://www.youtube.com/@diabetesconnections Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's In the News.. a look at the top news stories in the diabetes community over the past seven days. This week, The US FDA gives the green light to Dexcom's G7 CGM, Mark Cuban's Cost Plus Pharmacy puts out a survey all about insulin, new studies looking at teens with type 1 and blood pressure as well as CGM and hospitalizations at the VA and much more! Previous episodes on Dexcom's G7: https://diabetes-connections.com/?s=g7 Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Our top story is big news.. Dexcom's G7 gets FDA approval. This device with a shorter, half hour warm up time, with the sensor and transmitter all in one piece was approved for people age 2 and up with all types of diabetes. It was approved as an iCGM as expected, which is good news for the automated systems the G6 currently works with.. much more to come of course, we've done a lot of episodes on the features and design of the G7 so I'd urge you to listen to those if you haven't yet and of course we'll follow up with a new episode with Dexcom as soon as they'll talk to me! XX In other news.. Illinois Attorney General files a fraud lawsuit, accusing Eli Lilly, CVS Pharmacy, Novo Nordisk and several other pharmaceutical companies of artificially inflating the cost of insulin by over 1,000% since the late 1990s. The complaint singles out Eli Lilly in particular, noting the price for a dose of its analog insulin Humalog rose by 1,527% between 1997 and 2018. "Remarkably, nothing about these medications has changed," the complaint states. "Today's $350 insulin is the exact same drug defendants originally sold for $20." The suit also notes that 13% of Illinoisans, about 1.3 million people, live with diabetes, making the pharma companies' alleged monopoly scheme a public health threat. There are several other state and class action suits against the insulin makers going through the courts right now. So far none have landed more than a glancing blow. https://www.courthousenews.com/illinois-attorney-general-sues-over-sky-high-insulin-prices/ XX A new contender, though, might be entering the arena. Mark Cuban's Cost Plus Pharmacy put out a tweet this week asking for feedback on adding insulin to their lower-cost inventory. Quote - Insulin users: we are evaluating a future insulin test program and would like your feedback. If we offered a 90-day supply of a fast-acting insulin (up to 12 vials/8 packs of pens) for $170 incl. shipping, what would you think?" There's a feedback form and I'll link that up in the show notes. https://forms.office.com/Pages/ResponsePage.aspx?id=nlWlyavTPES7xglhq5HvDwx1m5bO2mRDq1ekDvUshMtUNUZBM0dDUTA3RVpUOEY1WVNWVDE4U0JTMiQlQCN0PWcu XX People with diabetes who used glucose lowering drugs prior to getting COVID-19 seem to have fewer COVID-19 related adverse outcomes during hospitalization. The mediations have already been shown, albeit in conflicting findings, to have possible benefits regarding morbidity and mortality among patients with diabetes who become infected with COVID-19. These meds include orals like Metformin as well as injectables like sglt2 inhibitors like Jardiance and Invokana GLP-1 agonists like Ozempic and Trulicity. https://www.ajmc.com/view/glucose-lowering-drugs-may-reduce-risk-of-covid-19-related-adverse-events-in-patients-with-diabetes XX New research about opioids and diabetes. This study says people People with diabetes who underwent surgery had a significantly increased rate of prolonged opioid use (POU) compared to people without diabetes who underwent surgery. 56% higher for people with type 2 and more than 200% higher for those with type 1. This was a big, retrospective, observational study of more than 43,000 people who had operations at a single diverse healthcare system in 2008-2019. The researchers say this shows that in a real-world setting healthcare providers are generally not accounting for individual risk factors when prescribing postoperative opioids. https://www.medscape.com/viewarticle/985068 XX Teens with Type 1 diabetes (T1D) who took bromocriptine, a medication used to treat Parkinson's disease and Type 2 diabetes, had lower blood pressure and less stiff arteries after one month of treatment compared to those who did not take the medicine, according to a small study published in Hypertension, an American Heart Association journal

Jeff Dachis founded One Drop in 2014, after his own type 1 diagnosis. Known for its sleek meter design and more recently for on-demand telehealth services, One Drop is moving into something new. Jeff shares how that includes what they're calling a continuous health sensor. We'll talk about what that term means, how it could help people with diabetes and what Jeff is still really passionate about. More about One Drop: https://onedrop.today/blogs/press-releases/ada2022-cgm-biowearable-sensor-t2d This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's In the News.. a roundup of the top diabetes stories and headlines of the past seven days. This week: the first AID system to use Libre 3 is released, we learn more about Teplizumab, now brand name Tzield, to prevent T1D and how much it may cost. Couple of new research projects about what triggers type 1, a personal story about retinopathy and a player with T1D takes the stage at the World Cup. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX And by my new book "Still The World's Worst Diabetes Mom: More Real Life Stories of Parenting a Child With Type 1 Diabetes" available on Amazon in paperback and for kindle. XX XX The first automated insulin delivery system using the FreeStyle Libre 3 is now authorized in Germany. The mylife YpsoPump and the FreeStyle Libre 3, combined with the mylife CamAPS FX algorithm from CamDiab Ypsomed already launched mylife Loop in partnership with CamDiab in early summer 2022 in several countries. That was with the Dexcom G6. The company now says By enabling the FreeStyle Libre 3 sensor to work with mylife Loop, people with diabetes now have the option of choosing between two sensors, the Dexcom G6 and the FreeStyle Libre 3, and of customising their loop. with other European countries to follow in 2023. The mylife Loop offering is currently available for Android, iOS will follow in the second half of 2023. I spoke with Ypsomed last year, they are partnering with Lilly and plan to bring their pump the US. Right now oly the Dexcom G6 is approved for AID use, so we'll see if we get the same kind of flexibility. https://www.drugdeliverybusiness.com/ypsomed-camdiab-insulin-dosing-abbott-freestyle-libre-3/ XX Really interesting but very early work on protein known as Befa. It's produced by gut bacteria and triggers the division of cells that make insulin. Reserachers at Univesrty of Utah are working on understanding more about how Befa works.. hoping it could help them figure out a way to stimulate beta cell prdocution. The researchers' findings were recently published in the journal Cell Metabolism. The finding suggests that bacterial warfare in the gut can have collateral beneficial effects on the body, boosting the population of cells that can make insulin throughout the lifespan. In the future, Guillemin's team imagines possible therapeutic applications for the finding. For example, proactively fortifying the microbiomes of high-risk infants with BefA-producing bacteria could prevent them from later developing type 1 diabetes. https://scitechdaily.com/profound-implications-new-research-details-the-microbial-origins-of-type-1-diabetes/ XX A new serological test may be pivotal in the search for viral triggers of diseases like diabetes and celiac disease. PepSeq is a technology that allows scientists to test antibody binding against hundreds of thousands of protein targets at one time, instead of testing one at a time. This protocol is laid out in detail in an article published earlier in November in Nature Protocols. It's said to be an important step forward as concerns about bioterrorism, zoonotic diseases and the next pandemic are never far away. Understanding these pathogens will help scientists develop vaccines and track their movement and evolution. "This can help us to better understand the epidemiology of infectious diseases, and it is also empowering us in our search for potential viral triggers for non-infectious diseases like diabetes and celiac disease," Ladner said. https://medicalxpress.com/news/2022-11-serological-viral-triggers-diseases-diabetes.html XX The recent approval of teplizumab – brand name is now Tzield, for the delay of type 1 diabetes by the US Food and Drug Administration is expected to advance efforts to increase screening to cost-effectively identify those at risk for the condition who would be eligible to receive the new treatment. The anti-CD3 monoclonal antibody was approved November 17. In a clinical trial, teplizumab delayed the onset of clinical (stage 3) type 1 diabetes by approximately 2 years, and longer in some cases.. more than 4 years. It is administered by intravenous infusion once daily for 14 consecutive days and is expected to cost in the region of $200,000 for the course of treatment. During an investor call on November 18, Provention Bio chief commercial officer Jason Hoitt said

We're in the holiday eating season right now.. difficult enough to manage without diabetes. What can we do to take off some of the pressure this time of year while still enjoying holiday meals and parties and treats? JoAnne Robb is a therapist who has three children.. two with type 1. We talk about a lot more than food and holidays.. and as you can hear, she feels pretty strongly about some of the advice that's out there right now. More info about JoAnne, including her upcoming webinar, Let Them Eat Cake? https://www.diabetessweettalk.com/ This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

Stacey talks a lot about her son with type 1 but, as many of you know, she also has a daughter who doesn't have diabetes. What's it like to grow up with a sibling who gets more attention for something you can't do anything about? Lea was five when her little brother was diagnosed – she's now 21 and she has a lot to say. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's in the News.. the top diabetes stories of the past seven days. This week, the first drug to prevent T1D for any length of time is approved, Eli Lilly takes a financial hit from a Twitter impersonation stunt, Medtronic's 7-day pump infusion set is ready for consumers, Dexcom's G7 gets great reviews from older folks and educators for ease of use, a new study about light at night and diabetes and more! Learn more about the T1D Exchange: www.t1dexchange.com/stacey Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX And by my new book "Still The World's Worst Diabetes Mom: More Real Life Stories of Parenting a Child With Type 1 Diabetes" available on Amazon in paperback and for kindle. XX Our top story this week, the US U.S. Food and Drug Administration approves teplizumab, the first drug to delay the onset of type 1 diabets. We've been following this for a long time and I'll ink up our previous interviews with Provention Bio, the company that makes it. The brand name will be Tzield (teplizumab-mzwv) and it's an injection to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes. Tzield is administered by intravenous infusion once daily for 14 consecutive days. Lots of questions here and we'll follow up with an interview and more as soon as I can. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-can-delay-onset-type-1-diabetes https://diabetes-connections.com/delaying-a-t1d-diagnosis-the-fda-considers-teplizumab/ XX Our top story this week – the kerfuffle over on Twitter where a couple of accounts spoofed Ely Lilly. The insulin makers stock tanked 6% over just one day late last week, wiping billions of dollars from its market cap. On Nov.10, someone pretending to be Lilly's corporate account tweeted: "We are excited to announced insulin is free now." You may know that Twitter under new owner Elon Musk was verifying any account with any name for just 8-dollars. Another verified but fake Lilly account tweeted profanities and taunted people who use insulin with higher pricing, again, also fake. Other major insulin makers Sanofi and Novo Nordisk were also caught up in the crossfire, with their stock prices dipping and questions over the high cost of insulin back in the headlines. In the understatement of the year, Lilly CEO David Ricks said – quote – "it probably highlights that we have more work to do to bring down the cost of insulin for more people" XX Mice with diabetes appeared cured after transplantation of insulin-secreting pancreatic islet cells, according to a Stanford Medicine study. The animals' immune systems were coaxed to accept the donated cells prior to transplantation through a three-pronged process that could be easily replicated in humans, the researchers said. No immune-suppressing treatments were necessary after the transplant to prevent rejection of the foreign islet cells. The technique, which builds on earlier work at Stanford Medicine, may open the door to a new type of organ transplant that doesn't require an immunologically matched donor or years on immune-suppressing medication. The difference here is that they do two transplants.. first doing a partial blood stem cell transplant which makes the new pancreas cells recognized as the body's own and less likely to be rejected. Long way to go here, but promising idea. https://med.stanford.edu/news/all-news/2022/11/islet-transplant-diabetes.html XX The first and only 7-day infusion set is ready to go.. after approval more than a year ago – in September of 2021, Medtronic says customers can now order the Medtronic Extended for the 600 and 700 series pumps. In clinical studies of the Medtronic Extended infusion set, study participants observed a decrease in the number of times an infusion set needed to be changed by 50% and the number of infusion set failures associated with high glucose levels was lowered.3,4 Study participants using the Medtronic Extended infusion set commented on the new infusion set being more comfortable to wear compared to their previous infusion sets and were happy with the longer wear feature in helping reduce the overall burden of insulin pump therapy.3,4 Additionally, use of the Medtronic Extended infusion set is estimated to result in annual costs savings o

Eversense is a CGM that goes under the skin and stays there for up to six months. The company that makes it has big plans to make that time period longer and to make the sensor even more accurate. Stacey talks to Senseonics Chief Medical Officer Dr. Francine Kaufman. They had a wide ranging conversation about everything from sensor length to interoperability and working with different pump systems as well as access and so much more. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's in the News.. the top diabetes stories of the past seven days. This week, one state caps not just insulin prices, but diabetes supplies for some, Lilly is out with a new integrated pen system, new study look at DKA at diagnosis of type 1 and what that means for health issues later on, and more! Learn more about the T1D Exchange: www.t1dexchange.org/stacey Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX And by my new book "Still The World's Worst Diabetes Mom: More Real Life Stories of Parenting a Child With Type 1 Diabetes" available on Amazon now. XX Delaware Governor John Carney last month signed Senate Bill 316, which will cap the monthly cost of diabetes supplies and equipment at $35 for those on state insurance plans. This law will make blood glucose meters and strips, urine testing strips, syringes, continuous glucose monitors (CGM) and supplies, and insulin pump, and pump supplies more affordable and accessible. Senate Bill 316 will apply to state-regulated health plans and state employee plans, which will take effect in 2023 and 2024, respectively. The $35 per month cap includes deductible payments and cost-sharing amounts charged once a deductible is met. The cap does not, however, apply to high deductible health plans or catastrophic health plans. Although much of the conversation about diabetes costs focuses on insulin, diabetes supplies are also a significant cost for people with diabetes. According to the American Diabetes Association (ADA), people with diabetes have medical expenses of about 2.3 times higher than those without diabetes. Diabetes supplies account for about 15 percent of diabetes medical expenses. On average, people with diabetes, even those with private insurance, spend $490 out-of-pocket on diabetes-related supplies each year. https://diatribe.org/delaware-caps-monthly-cost-diabetes-supplies-35 XX New report estimates 1 point 3 million adults with diabetes have rationed their use of insulin within the last year. That's 16.5 percent of everyone who's been prescribed insulin. We told you about this report published last month in the journal Annals of Internal Medicine. It's getting more attention – and it should – as the Washington Post picked it up for a series of reports their doing on health stats. The report attributes the rationing to the cost of the drug and what it describes as "inadequate" insurance coverage. The price of the four most popular types of insulin has tripled in the past decade, according to the American Diabetes Association. https://www.washingtonpost.com/wellness/2022/11/08/diabetes-insulin-rationing/ XX One of the insulin makers will begin rolling out a new diabetes management platform in the next few weeks. Lilly is launching the Tempo platform, which includes prefilled, disposable Tempo Pens for insulin delivery with the compatible TempoSmart mobile app and the Tempo Smart Button, which is designed to track the pens' insulin dosages.The Tempo Smart Button was cleared by the FDA in mid-September, Lilly said in this week's announcement. When attached to the top of a Tempo insulin pen, it takes in and stores insulin dosing data, then automatically transfers that information to the TempoSmart app. TempoSmart can connect to a variety of other devices and apps, like Dexcom's continuous glucose monitors and Lilly's own blood glucose monitor, among others, but also from more general health-tracking wearables like those from Fitbit, Garmin, Google and Apple. https://www.fiercebiotech.com/medtech/eli-lilly-lines-launch-diabetes-management-platform-tracks-insulin-pen-use-blood-sugar XX XX New research at Georgia Tech shows promise in beta cell transplantation without having to take additional immunosuppressive drugs. This is cell therapy with a new biomaterial called iTol-100. That's the basis of a new startup called iTolerance. Long way to go here but a lot of promise for many other conditions as well at type 1. This is less cell encapsulation, as other companies are working toward, but it's more of a soft material that can mix right with the cells at the time of transplant. This research started with a three year grant from JDRF. https://www.research.gatech.edu/new-startup-develops-potential-cure-type-1-diabetes XX Not a big surprise, but children diagnosed while in DKA can increase the risk of health is

Type One Talks is a popular YouTube channel with videos that help manage all sort of technology and situations around diabetes. But its host and founder says he wasn't always that interested a diabetes deep dive. It all changed with his first CGM. Tom was an accountant in his former life so he really does love numbers. We'll talk about his diagnosis as a child in the former Czechoslovakia, how much everything has changed and why he started making videos about diabetes technology, basically experimenting on himself. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's in the News.. the top diabetes stories of the past seven days. This week: new research looks at off-label use of GLP and SGLT drugs for people with type 1, Medtronic gets 780G approval in Canada, finger prick early detection of type 1, and lots going on for Diabetes Awareness Month. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX And by my new book "Still The World's Worst Diabetes Mom: More Real Life Stories of Parenting a Child With Type 1 Diabetes" available on Amazon now. XX Our top story this week, Researchers say a blood test for early diagnosis of type 1 diabetes can stave off serious illness and hospitalization in children. This Australian study looked at the finger prick sample that is collected in the home and mailed to the lab. It included more than 17-thousand children and young adults, mostly in families with a history of type 1. The team of researchers are the first to use this method to screen diabetes in Australia. They said, We want to make type 1 diabetes screening accessible to every Australian child no matter where they live. Our recent work has proven that we can do this cheaply, accurately, and conveniently," The study is published in Pediatric Diabetes. https://medicalxpress.com/news/2022-11-home-screening-diabetes.html XX Medtronic gets the okay from Canada for it's MiniMed 780G system. It's now available in more than 60 countries around the world, with the U.S. notably missing from the list. Current 770G users will be able to upgrade their devices with the new system's software. The MiniMed 780G is equipped with Medtronic's SmartGuard technology, a hybrid closed-loop system what works with Medronic's CGM. It's approved for ages 7-80. Medtnoic submitted to the FDA in the spring of 2021, nearly a year after securing CE mark approval in Europe. The U.S. sign-off has been slow to arrive, however, thanks in large part to the FDA's discovery of quality control issues at the California headquarters of Medtronic's diabetes business. A December 2021 letter from the agency outlined shortfalls it discovered at the Los Angeles-area facility in a routine inspection, prompting Medtronic to implement corrective actions and other process improvements to address the issues. https://www.fiercebiotech.com/medtech/still-awaiting-us-approval-medtronics-auto-adjusting-insulin-pump-lands-canadian-nod XX XX People with type 1 diabetes who take GLP-1 receptor agonists or SGLT-2 inhibitors in real life seem to line up with controlled trials. The GLP-1 medicines have brand names like Ozempic or Trulicity and the SGLT-2 are Invokana or Jardiance. These are newer medications and people with type 1 are cautioned to take them carefully because of the higher risk of DKA. However, these researchers say after 12 months of use people taking a GLP-1 receptor agonist had a significant reduction in glycated hemoglobin (HbA1c), from an average of 7.7% to 7.3% (61 to 56 mmol/mol), as well as in bodyweight, from an average of 90.4 to 85.4 kg. and they used less insulin overall. SGLT2 inhibitors were used by 39 study participants for an average duration of 24.2 months, mostly with the intent to achieve better glycemic control (73.3%), but also for weight loss (37.8%), reduced insulin requirements (26.7%), and reduced glucose variability (24.4%). Also, about 12% of users initiated SGLT2 inhibitors for their beneficial cardiovascular or renal properties. In line with clinical trial findings, these real-world users had significant reductions in average HbA1c after 12 months of use, from 7.9% to 7.3% (63 to 56 mmol/mol), and in basal insulin dose, from a daily average of 31.3 to 25.6 units, but not in bolus insulin. And contrary to the results of controlled trials, although SGLT2 inhibitor users had a weight reduction, this was small and not statistically significant, at an average of 89.2 and 87.5 kg before and after 12 months, respectively. https://www.medwirenews.com/diabetes/real-world-adjunctive-medication-outcomes-type-1-diabetes/23662504 XX Taking a personalized approach to kidney disease screening for people with type 1 diabetes (T1D) may reduce the time that chronic kidney disease (CKD) goes undetected. The finding, published in Diabetes Care(link is external), provides the basis for the first evidence-based kidney screening model for people with T1D. Current C

When it comes to using a CGM, the first question you may ask is, "How quickly can I get one?!" But this week, you'll hear there are a few other questions you may want to ask in order to get the most out of continuous glucose monitoring. In this excerpt from "Still the World's Worst Diabetes Mom: More Real Life Stories of Parenting a Child With Type 1 Diabetes," Stacey lays out conversations to have BEFORE you decide whether and how to use a CGM. Thinking this out can make your child's use of a CGM more effective and with less stress for you. It may even be helpful for adults considering sharing their CGM information. Stacey's new book is now available on Amazon, Target wherever you get books online. The audiobook will be out in a few weeks. Check out Stacey's books: The World's Worst Diabetes Mom & Still The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

The author of Six Until Me, Kerri Sparling, isn't blogging any more, but she's still looking for stories of connection and community built around conversation For 14 years Kerri wrote a daily blog about her experience with type 1. She put aside SixUntilMe in 2019. We're going to talk about her new book, what she thinks about the online community these days and what's next. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's It's "In the News…" a look at the top diabetes stories and headlines of the past seven days. This week: a troubling new study about how many people with diabetes ration insulin, a new study looks at OpenAPS compared to traditional pumps, more research on Beta Bionics' iLet pump, an old diabetes drug might help in the fight against dementia, and more! Learn more about the T1D Exchange: https://t1dexchange.org/stacey/ Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX A new study shows nearly 1 in 5 adults in the U.S. with diabetes either skipped, delayed or used less insulin than was needed to save money. That comes out to roughly 1.3 million adults, or 16.5% of those who need insulin. The findings were based on data from the 2021 National Health Interview Survey, which is conducted annually by the Centers for Disease Control and Prevention and which interviews tens of thousands of Americans about their health-related experiences. It was the first time that the CDC had included questions about insulin use, though concerns about sky-high insulin prices have been reported for years. Starting Jan. 1, the Inflation Reduction Act, signed into law by President Joe Biden in August, will cap the monthly cost of insulin at $35 for seniors on Medicare. The bill, however, will leave out millions of Americans with private health insurance as well as those who are uninsured. It was also found to be more common among people with type 1 diabetes, at 18.6%, compared to those with type 2 diabetes, at 15.8% https://www.nbcnews.com/health/health-news/insulin-prices-many-adults-diabetes-ration-insulin-study-finds-rcna52287?cid=sm_npd_nn_tw_ma XX New islet cell transplant study looks very promising. Long term outcomes of two phase 3 clinical trials shows many patients didn't need insulin to maintain their blood sugar for up to eight years. It also showed that a new approach required fewer transplants than typical and was exceedingly safe. These trials included people who had kidney transplants and showed islet cell transplants for those people was safe and effective. 75 percent who initially were able to come off insulin therapy, more than half maintained total insulin independence, meaning they needed no additional insulin injections throughout the years of follow-up. https://www.pennmedicine.org/news/news-releases/2022/october/new-islet-transplant-method-leads-to-insulin-independence XX Study out of New Zealand looked at DIY diabetes tech and compared to some commercial offerings. Not sure what they were tyring to prvoe here because they looked at a closed loop system OpenAPS and compared it to a regular old pump and CGM system with no automation. No surprisingly, the people with type 1 in the AID group had much more time in range – about 14 percent more – than those using a standalone pump and CGM. No severe lows or DKA in either group. But these days, IMO, looking at an automated insulin delivery system to a pump and CGM that don't communicate is like comparing apples and chain saws. https://www.medtechdive.com/news/do-it-yourself-artificial-pancreas-diabetes/633888/ XX More good news for the iLet Bionic Pancreas. A clinical trial, conducted at 16 clinical sites across the United States, enrolled 326 participants ages 6 to 79 years who had type 1 diabetes and had been using insulin for at least 1 year. Participants were randomly allocated to a treatment group using the bionic pancreas or a standard-of-care control group that continued with their pre-trial method of glucose monitoring and insulin dosing. In participants using the bionic pancreas, A1C improved from 7.9% to 7.3%, yet remained unchanged among the control group. The iLet doesn't use carb counting – just meal announcements and it sets basal rates with just the user's body weight. It's currently in front of the US FDA, awaiting approval. XX Insulet issued an urgent medical device correction on Monday related to battery problems with a component of its Omnipod DASH system. The device uses a wearable insulin pod that's controlled by a personal diabetes manager (PDM), a smartphone-like device that does the calculations for bolus insulin doses. Insulet plans to replace the PDMs for all of its current Omnipod DASH users globally, incurring an aggregate charge of $35 million to $45 million, J.P. Morgan Analyst Robbi

Who would volunteer to spend a weekend with a bunch of teens with type 1? A bunch of people who've been there! We're talking about teen retreats – and what even adults can learn – about the power of connection. Patrick Mertes has lived with type 1 since he was a child. If that name sounds remember, he's one of the climbers from the 50-in-50 project where he and a friend climbed the highest peak in all 50 states in 50 days a couple of years back. He also runs a fantastic family and teen retreat in North Carolina. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's It's "In the News…" a look at the top diabetes stories and headlines of the past seven days. This week: Provention Bio hopes to get FDA approval of Teplizumab next month and partners with Sanofi on this T1D prevention drug, new type 2 studies show that younger people who develop it generally have worse health outcomes, Medicare considers expanded coverage of CGMs and more Learn more about the T1D Exchange: www.T1Dexchange.org/Stacey Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Provention Bio partners with Sanofi to help bring teplizumab to market. Teplizumab isn't yet approved, the FDA is expected to give it the thumbs up later this year.. this is the drug shown to prevent type 1 diabetes for up to three years. Among other things, Sanofi will get exclusive global marketing rights for the drug. The FDA had asked for more information the last time teplizumab was up for approval.. the three month period for that closes in November.. and a ruling is expected then. https://www.fiercepharma.com/pharma/proventions-regulatory-odyssey-diabetes-nears-its-end-company-taps-sanofi-marketing-assist XX New research has found that the age at which people are diagnosed with type 2 diabetes is associated with a higher risk of developing serious complications. The study, which was published in JAMA Network Open, analyzed health data from more than 36,000 Americans aged 50 and above. The researchers found that those who were diagnosed with type 2 diabetes between the ages of 50 and 59 had "elevated risks" of heart disease, stroke, disability, cognitive impairment, and early death. But when people were diagnosed with diabetes later in life, the risks were reduced.1 No obvious reason for that.. but the researchers say it does point to the need for more screening and better prevention and treatment. https://www.verywellhealth.com/type-2-diabetes-diagnosis-age-6747897 XX The Centers for Medicare and Medicaid Services has proposed new draft coverage guidelines for continuous glucose monitors. Under the proposal, the CMS would cover CGMs for diabetes patients who are treated with insulin or "have a history of problematic hypoglycemia," as defined by the frequency or severity of low blood sugar events, seemingly regardless of whether they have Type 1 or 2 diabetes. Analysts at J.P. Morgan said the proposal reads "very favorably" for Abbott and Dexcom, leading CGM manufacturers that are targeting the "massive and highly under-penetrated Type 2 market opportunity." https://www.medtechdive.com/news/dexcom-abbot-CGM-diabetes-coverage/633577/ XX Mark cuban's Cost Plus Drugs has joined with @RocheDiabetesUS to provide our patients with their line of Accu-ChekⓇ test strips, lancets, & meters! This partnership will allow anyone to access what they need to check their blood sugar, at a low price. XX Researchers who study Type 2 diabetes have reached a stark conclusion: There is no device, no drug powerful enough to counter the effects of poverty, pollution, stress, a broken food system, cities that are hard to navigate on foot and inequitable access to health care, particularly in minority communities. This is a long and complicated article published in the New York Times.. I'll link it up and I urge you to read it. I can't really to it justice in a short excerpt here. "Our entire society is perfectly designed to create Type 2 diabetes," said Dr. Dean Schillinger, a professor of medicine at University of California, San Francisco. "We have to disrupt that." Dr. Schillinger and nearly two dozen other experts laid out a road-map for doing so earlier this year in a comprehensive national report to Congress on diabetes, the first of its kind since 1975. It calls for reframing the epidemic as a social, economic and environmental problem, and offers a series of detailed fixes, ranging from improving access to healthy food and clean water to rethinking the designs of communities, housing and transportation networks. https://www.nytimes.com/2022/10/05/health/diabetes-prevention-diet.html XX Back to the news in a moment but first.. The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidentia

We're taking a look at the design decisions that go into diabetes technology, specifically Dexcom's G7. Beyond the accuracy and interoperability we all want, they also look at things like dexterity, feel and hand strength. Alex Diener is Dexcom's Senior Director of Global Product Design. He lives with type 1 and he shared a lot of the behind the scenes thought process that's gone into the design of the G7 sensor and transmitter and the apps that go along with it. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Halloween webinar for parents: https://us02web.zoom.us/webinar/register/WN_0Xaaj9hoR-u96Kxm-OjfSQ Moms' Night Out event: https://diabetes-connections.com/diabetes-connections-presents-moms-night-out/ Check out Stacey's books and use promo code "Spooky" to save $3! More about Dexcom: Our interviews with CEO Kevin Sayer: https://diabetes-connections.com/?s=sayer Our interviews with COO Jake Leach: https://diabetes-connections.com/?s=leach Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's "In the News…" a look at the top diabetes stories and headlines of the past seven days. This week: Michigan joins California in exploring producing and distributing insulin made in-state, new study looks at why girls have a harder time with T1D than boys, weekly basal insulin moves forward, Dexcom puts G7 in wider release (but not yet in the US) and more! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Michigan following California when it comes to exploring making and distributing insulin. Governor Gretchen Whitmer signed an executive directive this week to establish a Michigan-based insulin manufacturing facility, and facilitate the development, in conjunction with a partner or partners, of a low-cost insulin product for distribution in Michigan. Whitmer already announced a plan to cap insulin costs in her State of the State address in January. https://michiganadvance.com/blog/whitmer-signs-directive-seeking-to-lower-insulin-costs-wins-bipartisan-praise/ XX Novo Nordisk plans to move forward with its once a week insulin icodec. Recent studies show it worked as well or better than daily basal insulin, reducing A1C after 52 weeks. Novo Nordisk's ONWARDS program for once-weekly insulin icodec comprises six phase 3a global clinical trials, including a trial with RWE involving more than 4,000 adults with type 1 or type 2 diabetes. It is expected that Novo Nordisk will file for regulatory approval of the once-weekly insulin icodec in the first half of 2023 in the US, the EU, and in China. There is a separate and additional study for people with type 1 – looking at weekly insulin icodec wth mealtime insulin. That's expected to conclude in about six months. https://pharmaphorum.com/news/novo-nordisk-achieve-headline-results-with-icodec-insulin/ XX Big new study shows that girls tend to have more serious issues with type 1 diabetes than boys. This is physical, quantifiable stuff, including higher blood sugar levels, weight issues, and higher cholesterol. This was a review of 90 previous studies at Amsterdam University Medical Centers. that women and girls have typically not received as much attention as study subjects as men. These researchers say more study is needed including finding ways to help doctors treat girls with type I diabetes differently than boys https://www.healthline.com/health-news/why-type-1-diabetes-can-be-tougher-on-girls-than-boys XX Alarming new study says that cases of type 1 worldwide could double by 2040. Tracking has improved in recent years, but Type 1 diabetes is underrepresented. In addition, because many countries don't collect Type 1 diabetes data, the numbers have historically skewed toward North America and Europe. About 175,000 people worldwide died because of Type 1 diabetes in 2021, they believe, and 63 to 70 percent of the deaths in those under age 25 occurred because the disease wasn't diagnosed. This study is in the Lancet Diabetes and Endocrinology https://www.washingtonpost.com/health/2022/10/03/diabetes-type-one-surge/ XX Big new study looking at which drugs paired with Metformin work the best for type 2. The trial was conducted at 36 study centers nationwide with more than 5000 people. Three groups took metformin plus a medicine that increased insulin levels: sitagliptin or Januvia, liraglutide or Victoza, or glimepiride or Amaryl. The fourth group took metformin and a long acting insulin. After about five years of follow-up, the researchers found that all four drugs improved blood glucose levels when added to metformin. But those taking metformin plus liraglutide or the long-acting insulin achieved and maintained their target blood levels for the longest time. The effects of treatment did not differ with age, sex, race, or ethnicity. However, none of the combinations overwhelmingly outperformed the others. https://www.nih.gov/news-events/nih-research-matters/popular-diabetes-drugs-compared-large-trial XX Dexcom's G7 is getting a wider rollout: the United Kingdom, Ireland, Germany, Austria and Hong Kong, with launches in New Zealand and South Africa in the coming weeks. I'll link up the promotional video.. no news yet from the US FDA on when the G7 will be approved in the US. I am talking to Dexcom's Senior Director of Global Product Design for Tuesday's podcast episode. https://www.youtube.com/watch?v=dYqNUf0paAU

Many of you tuned in virtually to EASD or maybe you were lucky enough to travel there! There was one talk at the European Association for the Study of Diabetes that really got my attention: the #dedoc° symposia "What we wish you knew — and why" which featured advocates speaking on topics that are relevant to people living with diabetes. The topic for this one is: Novel forms of online peer support developed during COVID; how did communities around the world stay connected? #dedoc° was founded in 2012 by Bastian Hauck, who created the Twitter hashtag #dedoc to host weekly TweetChats for the German chapter of the Diabetes Online Community. It acted as a catalyst to grow a small group of diabetes bloggers into one of Europe's strongest patient advocacy and peer support communities. This is an excerpt from the symposium – you can watch the entire thing including the Q&A at the end – at www.dedoc.org/symposium. Speakers: Renza Scibilia, Diabetes Australia Andrea Limbourg, France Jeff Hitchcock, Children with Diabetes, USA Salih Hendricks, South Africa Tom Dean, UK, Twitter DiabetesChat Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's "In the News..." a look at the top diabetes stories and headlines of the past seven days. This week: new information about COVID and type 1 in kids, a new way to look for diabetes before symptoms appear, Medtronic may be ready to ship their 7-day infusion set, approved more than a year ago, and more. Thanks to our sponsor, T1D Exchange: www.t1dexchange.org/Stacey Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX A pair of studies released within days of one another have produced conflicting reports related to the apparent increase in type 1 diabetes diagnoses following a COVID-19 infection in younger patients. one of the studies suggests a COVID-19 infection was associated with up to a 72% increase in new diagnoses of type 1 diabetes, the second, suggests while overall rates of diagnoses may be elevated, COVID-19 may not be the cause of increased prevalence. The second group says we need to consider what has happened regarding the spread of viruses such as enteroviruses during the pandemic, and whether there are any other environmental factors, such as sunlight exposure and vitamin D levels, that might have altered during lockdown that might also be relevant." The group whose findings suggest covid is the link are asking families with any family history of type 1 to watch for symptoms in the year following a child's Covid diagnosis. Both groups are pushing for more study, https://www.endocrinologynetwork.com/view/studies-debate-link-between-covid-19-and-increased-type-1-diabetes-diagnoses XX Insulin pricing legislation might get another look this year.. Sens. Jeanne Shaheen, D-N.H., and Susan Collins, R-Maine, are working to update a draft bill that would cap consumer copays for insulin in the commercial market and incentivize drugmakers to lower list prices. One of the bill's provisions capping Medicare copays at $35 a month was enacted as part of the Democrats' budget bill in August. The bill would extend the $35 Medicare copay cap to the commercial market. It would also ban health plans from requiring doctors' approval before prescribing a drug and prohibit manufacturer rebates when drugmakers freeze their list prices at 2021 Medicare net rates. Senate Majority Leader Charles E. Schumer has repeatedly voiced plans to bring the bill to the floor but the timeline keeps slipping. It's not expected this would make it in front of lawmakers again until after the midterms. https://rollcall.com/2022/09/28/lawmakers-eye-lame-duck-for-unfinished-business-on-insulin/ XX The Medtronic Extended infusion set (EIS) is the newest insulin pump infusion set from Medtronic and the first and only set that can be worn for twice the wear time! With the Extended infusion set and reservoir, patients can keep the infusion sites they prefer working longer while also benefiting from the easy insertion process currently available with the MiniMedTM MioTM Advance infusion set (which also means training is a breeze). The Medtronic Extended Insuion set worn on the arm. Components of the Medtronic Extended infusion set We know you're wondering how does this work? The EIS introduces innovative technology that allows for longer wear by mitigating the insulin degradation and preservative loss seen in 2–3-day infusion sets. Specifically, it is designed with tubing that features advanced materials to help reduce insulin preservative loss and maintain insulin flow and stability. It also has a new tubing connector that improves the physical and chemical stability of insulin by filtering out insulin fibrils. Fibrils are strands of destabilized insulin that clump together and can contribute to poor glycemia due to infusion set occlusion and immune response at the infusion site.1 Lastly, the EIS has an improved adhesive patch that extends wear-time and provides comfort, keeping the infusion set in place for up to 7 days. All these elements help to further reduce the burden on the patient. What if a patient uses more than 300 units of U-100 insulin in a 7-day period? No problem. Patients with increased insulin needs will also be able to benefit from using the Extended infusion set by simply changing their reservoir mid-way through their use of the set. To support these patients, innovative and simple training resources will be made available. Stay tuned for more details regarding the Medtro

Dexcom's G7 is still not approved in the United States, but it's in limited release in Europe. This week, friend of the show Kamil Armacki, better known as Nerdabetic, interviews Dexcom's Chief Operating Officer, Jake Leach. Find more about Kamil over at his amazing YouTube Channel here: https://www.youtube.com/c/nerdabetic This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's In the News! This week's top diabetes headlines and stories include: cybersecurity risk cited for some Medtronic pumps, Omnipod 5 gets European approval, new data about the Freestyle Libre and avoiding hospitalizations, the new T1D Index and more! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX XX potential cybersecurity risk for Medtronic MiniMed 600 Series Insulin Pump Systems. The FDA sent out an alert for multiple systems including the MiniMed 630 G and MiniMed 670G. They say this is a potential issue and that there have NOT been any reports of actually unauthorized access. Medtronic has issued an Urgent Medical Device Correction on their own website notifying users as well as providing recommended actions. If unauthorized access occurs, the pump's communication protocol could be compromised, which may cause the pump to deliver too much or too little insulin," noted the FDA's September 20 Cybersecurity alert. On their website, Medtronic provides the Urgent Medical Device Correction, a list of model numbers impacted by the issue, and a multitude of frequently asked questions for device users. Within these resources, Medtronic notes the issue was identified through an internal review and, while the event meets the definition of a recall, users are not required to return their devices. In a letter to users, which was signed by Chirag Tilara, vice president of Quality at Medtronic Diabetes, and Robert Vigersky, MD, chief medical officer at Medtronic Diabetes, the pair recommended all patients turn off the "Remote Bolus" feature on their pump if it is turned on, which is on by default. The letter also urged users to conduct any connection linking of devices in a nonpublic setting. Additional recommended precautions from Medtronic included keeping pump and connected system components within user control at all times, be attentive to pump notifications, alarms, and alerts, and immediately cancel any boluses you or your care partner did not initiate. The FDA urged those with questions to reach out to Medtronic at 1-800-646-4633, option 1. https://www.endocrinologynetwork.com/view/cybersecurity-risk-minimed-600-systems-alert-from-fda-medtronic XX Omnipod 5 gets the CE Mark, that's European approval for individuals aged two years and older with type 1 diabetes. This comes as Insulet presents new studies at the European Association for the Study of Diabetes (EASD) meeting in Stockholm, Sweden. https://www.businesswire.com/news/home/20220920005138/en/Insulet-Announces-CE-Mark-Approval-for-Omnipod%C2%AE-5-Automated-Insulin-Delivery-System XX Abbott says the Freestyle Libre system can help reduce diabetes-related hospitalizations. Data from the Real-World Evidence of Freestyle Libre (RELIEF) were presented this week. The retrospective study of the French national health claims database shows that the 5,933 people with Type 2 diabetes who were following a basal-only regimen and using the FreeStyle Libre system had 67% fewer ADE-related hospitalizations one year after initiating the FreeStyle Libre treatment. The data also show a 75% reduction in hospitalizations for diabetic ketoacidosis (DKA), a potentially life-threatening condition when glucose levels are too high for too long and ketone levels rise to dangerous levels in the blood, and a 44% reduction in admissions for severe hypoglycemia (low glucose levels). Further, the study showed sustained reductions in hospitalizations over a two-year period of FreeStyle Libre system use, regardless of whether the patients were under the care of a diabetes specialist or a general healthcare practitioner. https://www.mddionline.com/diabetes/can-abbotts-freestyle-libre-help-reduce-diabetes-related-hospitalizations XX A look at bone health and type 1 diabetes in teen girls. Small study herewith girls age 10-16.. found that the more sedentary had worse markers of bone health in imaging tests than girls without diabetes. When the groups had the same physical activity, no difference was seen regardless of diabetes. However, this is early research and further study is needed, the group cautions. However, if further, rigorous studies confirm these findings, "physical activity is potentially a really effective means of improving bone quality in kids with type 1 diabetes." https://www.medscape.com/viewarticle/981092 XX Back t

Researchers at UVA recently published a study called Design and Validation of an Open-Source Closed-Loop Testbed for Artificial Pancreas Systems. They say what they've set up here is quote - a valid tool that can be used by the research community to demonstrate the effectiveness of different control algorithms and safety features for APS, automated pancreas systems. This week, you'll hear from Xugui Zho and Homa Alemzadeh, two of the researchers on this study. Link to the study: https://arxiv.org/pdf/2208.06479.pdf This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's In the News! This week's top diabetes headlines and stories include: with more cases of type 1 and type 2 diabetes in US kids, researchers look into whether more screenings should take place. There's a new injectable on the market that some studies show can reduce the risk of type 2 diabetes in overweight and obese people, Medtronic faces a shareholder lawsuit and a 92-yar old Long Island woman, diagnosed as a child, may be one of the oldest living people with type 1. She has some great things to say about what helps her manage well all this time! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*